...
首页> 外文期刊>Lab on a chip >Cancer marker-free enrichment and direct mutation detection in rare cancer cells by combining multi-property isolation and microfluidic concentration
【24h】

Cancer marker-free enrichment and direct mutation detection in rare cancer cells by combining multi-property isolation and microfluidic concentration

机译:通过组合多性分离和微流体浓度,通过组合巨癌细胞在稀有癌细胞中无癌症的富集和直接突变检测

获取原文
获取原文并翻译 | 示例
           

摘要

Genetic analysis, rather than simply counting the number of circulating tumor cells (CTCs), which are rare cancer cells in peripheral blood, has great potential for non-invasive biopsy or "liquid biopsy." However, a practical problem in conventional enrichment of CTCs is that the isolated target cells are mixed with numerous residual leukocytes, and are suspended in a large volume. Hence, further isolation (i.e., cytokeratin (CK)-positive cell picking) or DNA purification is required for downstream genetic analysis after isolation. Here, we propose a novel cancer marker-free method of CTC enrichment by size-based Filtration and Immunomagnetic Negative selection followed by Dielectrophoretic concentration (CTC-FIND) for direct detection of genetic mutations in rare cancer cells suspended in whole blood. A combination of two independent isolation methods based on physical (filtration) and biochemical properties (immunomagnetic negative selection) in CTC-FIND allowed highly efficient cancer marker-free purification (5.1-log depletion of leukocytes). The isolated cells were trapped and concentrated using a microfluidic step-channel device using dielectrophoresis for discrimination and downstream genetic analysis. The feasibility of cancer marker-free enrichment by CTC-FIND was successfully demonstrated by directly detecting mutations in various cancer cells with a very high sensitivity of 1 cell per mL, including EpCAM and CK-negative cells, which were used to spike 8 mL of whole blood. Thus, CTC-FIND can be used with liquid biopsy to detect genetic mutations in wide-ranging CTC subsets, independent of cancer cell-specific marker expression.
机译:遗传分析,而不是简单地计算循环肿瘤细胞(CTC)的数量,这些肿瘤细胞(CTC)是外周血中稀有的癌细胞,具有巨大侵入性活组织检查或“液体活检”的潜力。然而,在CTC的常规富集中的实际问题是分离的靶细胞与许多残留的白细胞混合,并悬浮在大体积中。因此,在分离后下游遗传分析需要进一步分离(即,细胞角蛋白(CK) - 阳性细胞拣选)或DNA纯化。在这里,我们提出了一种通过基于尺寸的过滤和免疫磁性负选择的CTC富集的新型癌症无标记方法,然后是介电磁浓度(CTC-PRECE),用于直接检测稀有癌细胞中的稀有癌细胞中的遗传突变。基于物理(过滤)和生物化学特性(免疫磁性选择)在CTC中的两种独立隔离方法的组合 - 发现允许高效的癌症标记纯化(5.1-尾部耗尽白细胞)。使用微流体步进沟道装置捕获和浓缩隔离的细胞,使用介电流术进行辨别和下游遗传分析。通过直接检测各种癌细胞中的突变,通过每毫升的1个细胞的敏感性(包括EPCAM和CK阴性细胞)直接检测各种癌细胞中的敏感性,通过用于刺激8ml全血。因此,CTC-Fince可与液体活检一起使用以检测宽范围的CTC子集中的基因突变,与癌细胞特异性标记表达无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号